IP Library Granted Patent US 9,587,008
Granted Patent B2
US 9,587,008 · App. 14/475,881 · Granted Mar 7, 2017

Method of producing recombinant vitamin K dependent proteins

Inventors: William N. Drohan (Springfiled, VA); Michael J. Griffith (San Juan Capistrano, CA)
Assignee: APTEVO BIOTHERAPEUTICS LLC
C07K14/745A61K38/36C12N9/50C12P21/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,587,008
App. No.
14/475,881
Granted
Mar 7, 2017
Kind
B2
Abstract

Methods for producing cell lines with high levels of biologically active recombinant vitamin K dependent proteins are described. The transfected cell lines do not include heterologous genes for processing enzymes and are not subject to selection pressure such as methotrexate resistance. Cell lines producing Factor VII/VIIa and Factor IX are described. These cell lines can be used for isolation of Factor VII/VIIa and/or Factor IX for treatment of Hemophilia.

Claims (14)

1. A method of producing a vitamin K dependent protein, the method comprising the steps of: (a) transfecting a population of mammalian cells with a gene encoding the vitamin K dependent protein operably linked to a promoter, wherein the mammalian cells do not contain heterologous genetic material encoding proteins involved in the post-translation modification of the vitamin K dependent protein; (b) performing at least one round of cloning and screening to identify cells which produce at least 30 mg/L of the vitamin K dependent protein, wherein at least 10% of the vitamin K dependent protein is biologically active; (c) optionally, repeating step (b) one or more times; and (d) harvesting the vitamin K dependent protein.

2. The method of claim 1 , wherein the vitamin K dependent protein is selected from the group consisting of Factor II, Factor VII, Factor IX, Factor X, Protein C and Protein S.

3. The method of claim 2 , wherein the vitamin K dependent protein is Factor IX or Factor VII.

4. The method of claim 1 , wherein in step (b) the cloning is limit dilution cloning or semi-solid matrix cloning.

5. The method of claim 1 , wherein the promoter is a Chinese hamster elongation factor 1 (CHEF-1) promoter.

6. The method of claim 1 , further comprising the step of preselecting cells producing at least 10 mg/L vitamin K dependent protein before step (b).

7. The method of claim 1 , wherein the cells are cultured in a media that includes vitamin K.

8. The method of claim 1 , wherein the cells are cultured in a media that does not include vitamin K.

9. The method of claim 1 , wherein in step (b) at least 20% of the vitamin K dependent protein is biologically active.

10. The method of claim 9 , wherein at least 30% of the vitamin K dependent protein is biologically active.

11. The method of claim 10 , wherein at least 40% of the vitamin K dependent protein is biologically active.

12. The method of claim 1 , wherein the mammalian cells are Chinese hamster ovary cells.

13. A method of producing a vitamin K dependent protein, the method comprising the steps of: (a) transfecting a population of mammalian cells with a gene encoding the vitamin K dependent protein operably linked to a Chinese hamster elongation factor 1 (CHEF-1) promoter, wherein the mammalian cells do not contain heterologous genetic material encoding proteins involved in the post-translation modification of the vitamin K dependent protein; and (b) performing at least one round of cloning and screening to identify cells which produce at least 30 mg/L of the vitamin K dependent protein, wherein at least 10% of the vitamin K dependent protein is biologically active.

14. The method of claim 13 , wherein the cloning is limit dilution cloning or semi-solid-matrix cloning.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2025
From: BANK OF MONTREAL
To: APTEVO BIOTHERAPEUTICS LLC; MEDEXUS PHARMACEUTICALS, INC.; MEDEXUS PHARMA, INC.
Reel/Frame 072955/0496 →
RELEASE OF SECURITY INTEREST Recorded Mar 21, 2023
From: MIDCAP FINANCIAL TRUST
To: MEDEXUS PHARMA INC.; MEDEXUS PHARMACEUTICALS INC.; MI ACQUISITIONS, INC.,; APTEVO BIOTHERAPEUTICS LLC,
Reel/Frame 063049/0761 →
SECURITY AGREEMENT Recorded Mar 8, 2023
From: APTEVO BIOTHERAPEUTICS LLC
To: BANK OF MONTREAL, AS ADMINISTRATIVE AGENT
Reel/Frame 062992/0829 →
SECURITY INTEREST (REVOLVING) Recorded May 8, 2020
From: MEDEXUS PHARMACEUTICALS INC.; MEDEXUS INC.; MEDEXUS PHARMA, INC.; MI ACQUISITIONS, INC.; APTEVO BIOTHERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 052617/0579 →
RELEASE OF SECURITY INTEREST Recorded Mar 6, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: APTEVO THEAPEUTICS INC.; APTEVO BIOTHERAPEUTICS LLC; APTEVO RESEARCH AND DEVELOPMENT LLC
Reel/Frame 052039/0258 →
SECURITY INTEREST Recorded Mar 6, 2020
From: MEDEXUS PHARMACEUTICALS INC.; MEDEXUS INC.; MEDEXUS PHARMA, INC.; MI ACQUISITIONS, INC.; APTEVO BIOTHERAPEUTICS LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 052039/0633 →
SECURITY INTEREST Recorded Feb 7, 2019
From: APTEVO THERAPEUTICS INC.; APTEVO BIOTHERAPEUTICS INC.; APTEVO RESEARCH AND DEVELOPMENT LLC
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 048270/0813 →
MERGER Recorded Dec 14, 2016
From: CNJ HOLDINGS INC.
To: CANGENE CORPORATION
Reel/Frame 040735/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: CANGENE CORPORATION
To: 407850 MANITOBA PARTNERSHIP
Reel/Frame 040735/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2016
From: CANGENE CORPORATION; 407850 MANITOBA PARTNERSHIP; EMERGENT PROTECTIVE PRODUCTS CANADA ULC
To: APTEVO BIOTHERAPEUTICS LLC
Reel/Frame 040735/0833 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: GRIFFITH, MICHAEL J.
To: INSPIRATION BIOPHARMACEUTICALS, INC.
Reel/Frame 035263/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: DROHAN, WILLIAM N.
To: INSPIRATION BIOPHARMACEUTICALS, INC.
Reel/Frame 035263/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: INSPIRATION BIOPHARMACEUTICALS, INC.
To: CANGENE CORPORATION
Reel/Frame 035263/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2015
From: CANGENE CORPORATION
To: CNJ HOLDINGS, INC.
Reel/Frame 035263/0679 →
Continuity (4)
Continuation 13459743 · Apr 30, 2012
Continuation PCTUS2010054581 · Oct 28, 2010
Provisional Application 61256802 · Oct 30, 2009
Related Publication 20140369994A1 · Dec 18, 2014